Top picks in English

Danish Medicines Agency tightens requirements for chloroquine trial after serious side effects reported

The Danish Medicines Agency now requires increased reporting of side effects for clinical trials testing chloroquine as a cure for covid-19, after Swedish authorities found serious side effects when using the drug off-label.
Thomas Senderovitz, director of the Danish Medicines Agency | Foto: Martin Lehmann / Ritzau Scanpix
Thomas Senderovitz, director of the Danish Medicines Agency | Foto: Martin Lehmann / Ritzau Scanpix
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT

Malaria drug hydroxycholoroquine, also known as chloroquine, has been highlighted as a potential treatment for covid-19 by researchers around the world. However, after worrying reports from Sweden, the Danish Medicines Agency is strengthening its requirements for clinical studies of the drug.

Allerede abonnent?Log ind her

Læs hele artiklen

Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

Med din prøveperiode får du:

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
    • Skal indeholde mindst 8 tegn samt tre af disse: Store bogstaver, små bogstaver, tal, symboler
    Skal indeholde mindst 2 tegn
    Skal indeholde mindst 2 tegn

    Få fuld adgang til dig og dine kollegaer

    Start et gratis virksomhedsprøveabonnement

    Del artikel

    Relaterede artikler

    Tilmeld dig vores nyhedsbrev

    Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.

    Nyhedsbrevsvilkår

    Forsiden lige nu

    Læs også

    Job